Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multimodal AI-based Therapy Response Prediction and Risk Stratification for Esophageal Cancer

NCT07354295 is registered in ClinicalTrials.gov with Shu Peng as lead sponsor.

NCT NCT07354295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07354295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multimodal AI-based Therapy Response Prediction and Risk Stratification for Esophageal Cancer
Lead sponsor
Shu Peng
Phase
Observational
Overall status
Recruiting
Start date
July 26, 2025
Completion date
September 30, 2030
Enrollment
1,500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer